U.S. Food and Drug Administration Grants Full Approval for Balversa to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Balversa® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations
Phase 3 THOR Study Showed a 36 Percent Reduction in the Risk...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Food and Drug Administration (FDA) | Genetics | Grants | Study